20 / 38
AE, %
First-Line (grade 3-4)
Pretreated (grade 3-4)
Palbo + AI
1
Ribo + AI
2
Abema +
AI
3
Palbo +
Ful
4,5
Abema +
Ful
6
Ribo +
Ful
Neutropenia
56 + 10
50 + 10
20 + 2
53 + 9
24 + 3
Diarrhea
1 + 0
1 + 0
9 + 0
0
13 + 0
GOT
<1
7 + 2
6 + <1
2 + 0
2 + 0
GPT
0
5 + 1
4 + 0
3 + 0
4 + <1
QTc prol
NR
<1
NR
<1 + 0
NR
TEP/VE
NR + <1
<1 + <1
5 (grade?)
<1 + 0
2 (grade?)
CDK inh-based phase III clinical trial-based
Adverse Events
4
Turner NC, et al. N Engl J Med 2015;
5
Cristofanilli M, et al. Lancet Oncol 2016;
6
Sledge G, et al. J Clin Oncol 2017
1
Finn RS, et al. N Engl J Med 2016;
2
Hortobagyi G, et al. N Engl J Med 2016;
3
di Leo A, et al. J Clin Oncol 2017